Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894283 · ClinicalTrials.gov registry record · Early Phase 1
Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 198
- Enrollment target
NCT00894283: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT00894283 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 198 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00894283, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 198 participants
- Enrollment target
Study Summary
This pilot study is designed to determine the feasibility of conducting a randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice daily with respect to preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after bariatric surgery in obese patients.
Interventions
- DRUG Enoxaparin
- DRUG Fondaparinux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894283
The ClinicalTrials.gov registry entry for NCT00894283 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT00894283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894283 about?
NCT00894283 is a clinical study titled "Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients". This pilot study is designed to determine the feasibility of conducting a randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice daily with respect to preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after bariatric surgery in o...
What is the current status of trial NCT00894283?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 198 participants. The study started on 2009-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00894283?
The interventions under investigation include: Enoxaparin (DRUG), Fondaparinux (DRUG).
Who is sponsoring clinical trial NCT00894283?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.